MCID: PDT019
MIFTS: 31

Pediatric Fibrosarcoma

Categories: Cancer diseases

Aliases & Classifications for Pediatric Fibrosarcoma

MalaCards integrated aliases for Pediatric Fibrosarcoma:

Name: Pediatric Fibrosarcoma 12 15
Childhood Fibrosarcoma 74

Classifications:



External Ids:

Disease Ontology 12 DOID:3520
NCIt 51 C8088
UMLS 74 C0279981

Summaries for Pediatric Fibrosarcoma

MalaCards based summary : Pediatric Fibrosarcoma, also known as childhood fibrosarcoma, is related to adult mesoblastic nephroma and cellular congenital mesoblastic nephroma. An important gene associated with Pediatric Fibrosarcoma is NTRK3 (Neurotrophic Receptor Tyrosine Kinase 3), and among its related pathways/superpathways are Human Embryonic Stem Cell Pluripotency and Immune response IFN alpha/beta signaling pathway. The drugs Mechlorethamine and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and kidney, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Pediatric Fibrosarcoma

Graphical network of the top 20 diseases related to Pediatric Fibrosarcoma:



Diseases related to Pediatric Fibrosarcoma

Symptoms & Phenotypes for Pediatric Fibrosarcoma

GenomeRNAi Phenotypes related to Pediatric Fibrosarcoma according to GeneCards Suite gene sharing:

27 (show all 32)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-101 10.28 ETV6
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.28 EWSR1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.28 EWSR1 UBE2I
4 Increased shRNA abundance (Z-score > 2) GR00366-A-13 10.28 UBE2I
5 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.28 NTRK3
6 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.28 ETV6 EWSR1 NTRK3
7 Increased shRNA abundance (Z-score > 2) GR00366-A-140 10.28 EWSR1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.28 EWSR1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.28 ETV6
10 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.28 EWSR1 NTRK3 UBE2I
11 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.28 UBE2I
12 Increased shRNA abundance (Z-score > 2) GR00366-A-159 10.28 ETV6
13 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.28 NTRK1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.28 EWSR1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.28 UBE2I
16 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.28 ETV6
17 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.28 EWSR1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.28 ETV6
19 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.28 ETV6
20 Increased shRNA abundance (Z-score > 2) GR00366-A-3 10.28 UBE2I
21 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.28 NTRK3
22 Increased shRNA abundance (Z-score > 2) GR00366-A-41 10.28 NTRK3
23 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.28 EWSR1 NTRK3
24 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.28 NTRK1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.28 ETV6 EWSR1 UBE2I NTRK1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.28 UBE2I
27 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.28 NTRK1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.28 ETV6
29 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.28 UBE2I
30 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.28 EWSR1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.28 NTRK3 NTRK1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.28 EWSR1

MGI Mouse Phenotypes related to Pediatric Fibrosarcoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 9.56 BCOR ETV6 MYOD1 NTF3 NTRK1 NTRK3
2 no phenotypic analysis MP:0003012 9.1 ETV6 MYOD1 NTRK1 NTRK3 TPM3 UBE2I

Drugs & Therapeutics for Pediatric Fibrosarcoma

Drugs for Pediatric Fibrosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 68)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mechlorethamine Approved, Investigational Phase 3,Phase 2 51-75-2 4033
2
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
3
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
4
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 38904 498142
5
Dactinomycin Approved, Investigational Phase 3,Phase 2 50-76-0 457193 2019
6
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
7
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
8
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
9
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
10
Histamine Approved, Investigational Phase 3 51-45-6 774
11
Cyproheptadine Approved Phase 3 129-03-3 2913
12
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
13 Alkylating Agents Phase 3,Phase 1,Phase 2
14 Antineoplastic Agents, Alkylating Phase 3,Phase 1,Phase 2
15 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
16 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
17 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
18
Isophosphamide mustard Phase 3,Phase 2 0
19 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
20 Immunologic Factors Phase 3,Phase 2
21 Etoposide phosphate Phase 3,Phase 2
22 Antirheumatic Agents Phase 3,Phase 2,Phase 1
23 Antimitotic Agents Phase 3,Phase 1,Phase 2
24 Anti-Infective Agents Phase 3,Phase 2
25 Immunosuppressive Agents Phase 3,Phase 2
26 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2
27 Histamine Antagonists Phase 3
28 Neurotransmitter Agents Phase 3
29 Gastrointestinal Agents Phase 3
30 Serotonin Agents Phase 3
31 Serotonin Antagonists Phase 3
32 Anti-Allergic Agents Phase 3
33 Antipruritics Phase 3
34 Dermatologic Agents Phase 3
35 Histamine H1 Antagonists Phase 3
36
Histamine Phosphate Phase 3 51-74-1 65513
37
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
38
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 5284616 6436030
39
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
40
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
41
Vinorelbine Approved, Investigational Phase 1, Phase 2 71486-22-1 44424639 60780
42
Estramustine Approved, Investigational Phase 1, Phase 2 2998-57-4 259331 18140
43
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
44
Lenograstim Approved, Investigational Phase 2 135968-09-1
45
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
46
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
47
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
48
Mesna Approved, Investigational Phase 2 3375-50-6 598
49 Antibodies, Monoclonal Phase 2,Phase 1
50 Immunoglobulins Phase 2,Phase 1

Interventional clinical trials:

(show all 15)
# Name Status NCT ID Phase Drugs
1 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
4 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
5 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Completed NCT01614795 Phase 2 Temsirolimus
6 Combination Chemotherapy in Treating Patients With Advanced Cancer Completed NCT00004105 Phase 1, Phase 2 estramustine phosphate sodium;paclitaxel;vinorelbine ditartrate
7 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2 imatinib mesylate
8 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
9 Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer Completed NCT00002515 Phase 2 carboplatin;thiotepa;topotecan hydrochloride
10 Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma Terminated NCT00072280 Phase 2 cyclophosphamide;etoposide;ifosfamide;vincristine sulfate
11 Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Completed NCT00720174 Phase 1 Doxorubicin Hydrochloride
12 Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery Completed NCT00450736 Phase 1 celecoxib
13 Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas Completed NCT01567046
14 Genetic Study of Children With Soft Tissue Sarcoma or Rhabdomyosarcoma Completed NCT00003793
15 Glutamine in Preventing Oral Mucositis in Patients Receiving Chemotherapy for Sarcoma Withdrawn NCT00334984 Not Applicable glutamine

Search NIH Clinical Center for Pediatric Fibrosarcoma

Genetic Tests for Pediatric Fibrosarcoma

Anatomical Context for Pediatric Fibrosarcoma

MalaCards organs/tissues related to Pediatric Fibrosarcoma:

42
Bone, Bone Marrow, Kidney, Thyroid

Publications for Pediatric Fibrosarcoma

Variations for Pediatric Fibrosarcoma

Expression for Pediatric Fibrosarcoma

Search GEO for disease gene expression data for Pediatric Fibrosarcoma.

Pathways for Pediatric Fibrosarcoma

GO Terms for Pediatric Fibrosarcoma

Biological processes related to Pediatric Fibrosarcoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 cell differentiation GO:0030154 9.78 ETV6 MYOD1 NTRK1 NTRK3
2 positive regulation of synapse assembly GO:0051965 9.49 NTRK1 NTRK3
3 cellular response to nerve growth factor stimulus GO:1990090 9.46 NTRK1 NTRK3
4 activation of protein kinase B activity GO:0032148 9.43 NTF3 NTRK3
5 response to axon injury GO:0048678 9.4 NTRK1 NTRK3
6 positive regulation of actin cytoskeleton reorganization GO:2000251 9.37 NTF3 NTRK3
7 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.33 NTF3 NTRK1 NTRK3
8 positive regulation of phospholipase C activity GO:0010863 9.32 NTF3 NTRK3
9 nerve growth factor signaling pathway GO:0038180 9.26 NTF3 NTRK1
10 mechanoreceptor differentiation GO:0042490 8.96 NTRK1 NTRK3
11 neurotrophin signaling pathway GO:0038179 8.62 NTRK1 NTRK3

Molecular functions related to Pediatric Fibrosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.97 BCOR ETV6 EWSR1 MYOD1 NTF3 NTRK1
2 transcription factor binding GO:0008134 9.58 BCOR MYOD1 UBE2I
3 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 9.43 BCOR ETV6 MYOD1
4 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.37 NTRK1 NTRK3
5 GPI-linked ephrin receptor activity GO:0005004 9.16 NTRK1 NTRK3
6 neurotrophin binding GO:0043121 8.96 NTRK1 NTRK3
7 neurotrophin receptor activity GO:0005030 8.62 NTRK1 NTRK3

Sources for Pediatric Fibrosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....